The partnership centers around the Ancora Heart CORCINCH-HF pivotal clinical trial. It evaluates the safety and efficacy of the AccuCinch ventricular restoration system. Together, the companies aim to combine cutting-edge technology and expertise to deliver therapies to patients faster.
Egnite’s artificial intelligence (AI)-based Trial Accelerator technology helps to identify eligible patients for the trial. The Christ Health Network in Cincinnati, Ohio, first utilized the technology in CORCINCH-HF.
“Our goal with the development of the AccuCinch system is to provide a minimally invasive treatment option to further improve the lives of heart failure patients whose symptoms progress despite guideline-directed medical therapy,” said Mark Miles, chief commercial officer of Ancora Heart. “This partnership with egnite and The Christ Health Network will allow us to deploy AI tools such as egnite’s Trial Accelerator and expedite identification of eligible candidates for the CORCINCH-HF trial.”
How Egnite’s technology aids the Ancora Heart trial
The partnership aims to use the Egnite Trial Accelerator at other participating trial sites. It helps to drive patient identification and enrollment through AI and big data processing. The platform automatically screens hundreds of thousands of patients against the trial parameters. This helps identify more candidates without hospital staff dedicating hours to manual chart review.
Dr. Dean Kereiakes, president of The Christ Hospital Heart and Vascular Institute, called candidate identification a complex task. Kereiakes, the study’s principal investigator, said it requires many hours to review medical charts in the search for matching clinical criteria.
He added that the use of AI technology streamlines the trial screening process. It identifies candidates more quickly and efficiently, freeing up critical resources needed for clinical trial success.
“We are thrilled to partner with leading life sciences organizations like Ancora Heart and apply our novel technology to accelerate clinical trial enrollment,” said Joel Portice, president and CEO of Egnite. “We believe this collaboration is a significant step forward for patients and are excited to be at the forefront of cardiovascular care.”
